[EN] COMPOUNDS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS UTILES EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
申请人:FOCHON PHARMACEUTICALS LTD
公开号:WO2021233227A1
公开(公告)日:2021-11-25
Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
提供了某些PI3K抑制剂,其药物组合物以及使用方法。
PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF AS PI3K INHIBITOR
申请人:Medshine Discovery Inc.
公开号:EP3828184A1
公开(公告)日:2021-06-02
The present invention discloses a series of pyrazolopyrimidine derivatives and use thereof in preparing a medicament for treating a disease related to PI3K, and in particular, discloses a derivative compound of formula (I), a tautomer thereof or a pharmaceutically acceptable composition thereof.
Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists
申请人:Merck Sharp & Dohme Corp.
公开号:US11161819B2
公开(公告)日:2021-11-02
The present invention relates to a compound represented by formula (I):
and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
本发明涉及一种由式 (I) 代表的化合物:
及其药学上可接受的盐,可用于治疗或预防糖尿病、高脂血症、肥胖症、NASH、炎症相关疾病以及相关疾病和病症。这些化合物可作为 G 蛋白偶联受体 GPR120 的激动剂。还包括药物组合物和治疗方法。
[EN] PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF AS PI3K INHIBITOR<br/>[FR] DÉRIVÉ DE PYRAZOLOPYRIMIDINE ET SON UTILISATION COMME INHIBITEUR DE PI3K<br/>[ZH] 吡唑并嘧啶衍生物及其作为PI3K抑制剂的应用
SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS
申请人:Merck Sharp & Dohme Corp.
公开号:US20190161448A1
公开(公告)日:2019-05-30
The present invention relates to a compound represented by formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.